Showing results (331-340 of 812) with videos related to

Sort By:
Pageof 82
Expert Opinion on Investigational Drugs|October 13, 2015
Entrectinib: a potent new TRK, ROS1, and ALK inhibitorChristian Rolfo, Rossana Ruiz, Elisa Giovannetti, et al.
Breast Cancer Research and Treatment|May 1, 2009
ATM germline mutations in women with familial breast cancer and a relative with haematological malignancyLaura La Paglia, Anthony Laugé, Jérémie Weber, et al.
International Journal of Cancer|May 2, 2009
Functional analysis of the -2548G/A leptin gene polymorphism in breast cancer cellsMarianna Terrasi, Elena Fiorio, Anna Mercanti, et al.
The Breast Journal|May 7, 2010
Disentangling the roles of mammographic screening and HRT in recent breast cancer incidence trends in italy by analyses based on calendar time and time since screening activationEmanuele Crocetti, Carlotta Buzzoni, Fabio Falcini, et al.
Expert Opinion on Therapeutic Targets|March 27, 2012
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapiesLidia Rita Corsini, Giuseppe Bronte, Marianna Terrasi, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 28, 2008
Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipientsCandida C Quarta, Luciano Potena, Francesco Grigioni, et al.
World Journal of Gastroenterology|September 14, 2016
Multisciplinary management of patients with liver metastasis from colorectal cancerKathleen De Greef, Christian Rolfo, Antonio Russo, et al.
Expert Opinion on Therapeutic Targets|November 21, 2007
Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidenceAntonio Russo, Maria E Fratto, Viviana Bazan, et al.
Breast Cancer Research and Treatment|August 9, 2013
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditionsDaniele Fanale, Viviana Bazan, Lidia Rita Corsini, et al.
Expert Opinion on Investigational Drugs|November 4, 2014
Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategyGiuseppe Bronte, Francesca Lo Vullo, Gianfranco Pernice, et al.
Pageof 82